

VOLUME 46 / SUPPLEMENT 59 / SEPTEMBER 2015

EUROPEAN RESPIRATORY *journal*

OFFICIAL SCIENTIFIC JOURNAL OF THE ERS

Abstracts / *25th International Congress*
Amsterdam, Netherlands 26 –30 September 2015

Online ISSN: 1399-3003



ERS EUROPEAN
RESPIRATORY
SOCIETY

every breath counts

Copyright for individual abstracts remains with the authors.

This abstract supplement has been produced electronically by the European Respiratory Society. The European Respiratory Society is not responsible for errors or omissions in content. The ideas and opinions expressed in this publication do not necessarily reflect those of Coe-Truman and the European Respiratory Society. Products mentioned in this publication should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The European Respiratory Society assumes no responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in these abstracts. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. An effort has been made to check generic and trade names, and to verify drug doses. The ultimate responsibility, however, lies with the prescribing physician. Please convey any errors to scientific@ersnet.org.

Citations should be made in the following way: **Authors. Title. Eur Respir J 20015; 46: Suppl. 59, abstract number.**



Table Of Content

218. Pathogenic mechanisms of lung transplant complications: a focus on CLAD	2
PA1791: System biology (SB) allows the identification of pathogenic micro RNA (miR) in BOS	2

218. Pathogenic mechanisms of lung transplant complications: a focus on CLAD

PA1791

System biology (SB) allows the identification of pathogenic micro RNA (miR) in BOS

Simona Inghilleri², Stefano Di Carlo¹, Patrizia Morbini³, Fiorella Calabrese⁴, Gianfranco Politano¹, Davide Zampieri⁴, Alfredo Benso¹, Manuela Agozzino⁵, Emanuela Cova², Federica Meloni², Elena Rossi³

¹Control and Computer Engineering Dpt., Politecnico di Torino, Torino, Italy;


²Respiratory Diseases Dpt., IRCCS San Matteo Foundation, Pavia, Italy;

³Molecular Medicine, University of Pavia, Pavia, Italy; ⁴Thoracic and

Cardiovascular Sciences Dpt., University of Padua, Padua, Italy; ⁵Research

Transplant Laboratory, IRCCS San Matteo Foundation, Pavia, Italy

BOS is characterized by fibrotic bronchiolar obliteration. MicroRNAs (miRs), are small, non-coding, single stranded RNAs playing a role in many biological processes including EMT. Recent studies demonstrated a role of miRs in fibrotic disorders but evidence on BOS are lacking. We applied an SB approach and computationally identified and scored a limited panel of miRs potentially relevant in BOS. All pathways involved in BOS were included, enhanced using the ReNEs software, then list of intronic miRs was extracted. The initial panel of 54 candidates was scored (Coverage and ValCov scores) considering miR activity on pathways and previous validation. To validate SB analysis we selected, among miR with ValCov score >0.4, **miR21** (2° rank: 0.047) that was assessed by ISH on 3 samples: 3 mesenchymal cell lines (MC) derived from BAL of BOS pts, 2 lung BOS grafts of orthotopic rat lung Tx model (outbred CD SPF/VAF) and one explanted human BOS lung. MC lines expressed high level of miR21 with slight variation among lines. In addition, while native rat lung had no miR21 expression, a high degree of miR21 was documented in myofibroblasts of the OB lesion developed 15 days after Tx. Finally a very high degree of miR21 was documented in OB lesions of the BOS lung, while normal human lung had minimal miR21 positivity.



Our SB approach is validated and recognizes miR21 as a pathogenic factor and a possible therapeutic target in BOS.